CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.
作者信息
Thapa Bicky, Caimi Paolo F, Ardeshna Kirit M, Solh Melhem, Carlo-Stella Carmelo, Kahl Brad S, Hamadani Mehdi
机构信息
BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.
University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH.
出版信息
Blood Adv. 2020 Aug 25;4(16):3850-3852. doi: 10.1182/bloodadvances.2020002587.
Abstract
摘要
相似文献
1
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.弥漫性大B细胞淋巴瘤（DLBCL）中CD19抗体药物偶联物治疗并不排除随后对CD19导向的嵌合抗原受体（CAR）T细胞治疗产生反应。
Blood Adv. 2020 Aug 25;4(16):3850-3852. doi: 10.1182/bloodadvances.2020002587.
2
The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy.抗CD19抗体药物免疫偶联物Loncastuximab在接受抗CD19嵌合抗原受体T细胞（CAR-T）治疗后复发的弥漫性大B细胞淋巴瘤（DLBCL）中取得疗效。
Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e335-e339. doi: 10.1016/j.clml.2021.11.005. Epub 2021 Nov 12.
3
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.CD19 和 CD20 靶向嵌合抗原受体 T 细胞联合给药治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 II 期临床试验。
Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.
4
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.抗 CD19 嵌合抗原受体 T 细胞治疗后弥漫性大 B 细胞淋巴瘤的长程完全缓解。
Mol Ther. 2017 Oct 4;25(10):2245-2253. doi: 10.1016/j.ymthe.2017.07.004. Epub 2017 Jul 13.
5
Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.抗CD19嵌合抗原受体T细胞疗法：利用免疫系统的力量对抗弥漫性大B细胞淋巴瘤。
Curr Hematol Malig Rep. 2018 Dec;13(6):534-542. doi: 10.1007/s11899-018-0482-6.
6
CD19-directed CAR T-cell therapy in B-cell NHL.CD19 导向的 CAR T 细胞疗法治疗 B 细胞 NHL。
Curr Opin Oncol. 2020 Sep;32(5):408-417. doi: 10.1097/CCO.0000000000000668.
7
Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19-directed CAR T-cell therapy in diffuse large B cell lymphoma.纳武单抗在弥漫性大B细胞淋巴瘤中接受CD19导向的嵌合抗原受体T细胞疗法后未实现完全缓解的患者中的安全性和疗效。
Br J Haematol. 2023 Jul;202(2):434-436. doi: 10.1111/bjh.18775. Epub 2023 Mar 31.
8
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.Loncastuximab tesirine 用于治疗复发或难治性弥漫性大 B 细胞淋巴瘤。
Expert Opin Biol Ther. 2021 Nov;21(11):1373-1381. doi: 10.1080/14712598.2021.1973998. Epub 2021 Sep 10.
9
CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.针对 CD19 的免疫疗法治疗非霍奇金 B 细胞淋巴瘤患者。
Expert Opin Investig Drugs. 2018 Jul;27(7):601-611. doi: 10.1080/13543784.2018.1492549. Epub 2018 Jul 5.
10
Now you see me, now you don't: Isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment.你看得到我，转瞬又不见：CD19导向的嵌合抗原受体T细胞治疗后CD19阴性弥漫性大B细胞淋巴瘤的孤立性中枢神经系统复发
Cytopathology. 2022 Nov;33(6):757-759. doi: 10.1111/cyt.13160. Epub 2022 Jul 1.
引用本文的文献
1
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.原发性难治性和复发性弥漫性大B细胞淋巴瘤的治疗前景：最新进展与新兴疗法
J Hematol Oncol. 2025 Jul 1;18(1):68. doi: 10.1186/s13045-025-01702-5.
2
CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy.B细胞淋巴瘤中的CD19表达及CD19靶向治疗不断演变背景下的临床考量
World J Oncol. 2025 Apr;16(2):235-238. doi: 10.14740/wjon2534. Epub 2025 Mar 13.
3
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma.获批的针对大B细胞淋巴瘤的CD19靶向嵌合抗原受体T细胞的疗效相关因素。
Nat Rev Clin Oncol. 2025 Apr;22(4):241-261. doi: 10.1038/s41571-025-00992-5. Epub 2025 Feb 18.
4
Depletion of Tregs from CD4 CAR-T cells enhances the tumoricidal effect of CD8 CAR-T cells in anti-CD19 CAR-T therapy.在抗CD19嵌合抗原受体T细胞（CAR-T）疗法中，从CD4 CAR-T细胞中去除调节性T细胞（Tregs）可增强CD8 CAR-T细胞的杀瘤效果。
FEBS J. 2025 Apr;292(8):1904-1919. doi: 10.1111/febs.17326. Epub 2024 Dec 4.
5
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine.在使用loncastuximab tesirine后，采用嵌合抗原受体T细胞疗法对大B细胞淋巴瘤进行的真实世界治疗。
EJHaem. 2024 Sep 2;5(5):1110-1113. doi: 10.1002/jha2.993. eCollection 2024 Oct.
6
Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial.Loncastuximab tesirine治疗中国复发或难治性弥漫性大B细胞淋巴瘤患者：一项多中心、开放标签、单臂II期试验。
Haematologica. 2025 Mar 1;110(3):683-692. doi: 10.3324/haematol.2024.284973.
7
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.接受 tafasitamab 联合来那度胺治疗或 CAR T 细胞治疗前后的大 B 细胞淋巴瘤患者的结局。
Blood Adv. 2024 Oct 22;8(20):5371-5381. doi: 10.1182/bloodadvances.2024013726.
8
Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Loncastuximab Tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤。
Int J Mol Sci. 2024 Jul 10;25(14):7580. doi: 10.3390/ijms25147580.
9
The Evolving Role of Bridging Therapy during CAR-T Therapy.桥接治疗在CAR-T治疗中的角色演变
Clin Hematol Int. 2024 Jul 16;6(3):9-16. doi: 10.46989/001c.116261. eCollection 2024.
10
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.用抗体药物偶联物 loncastuximab tesirine 靶向 CD19 阳性淋巴瘤：作为单一药物和联合治疗的临床前活性证据。
Haematologica. 2024 Oct 1;109(10):3314-3326. doi: 10.3324/haematol.2023.284197.
本文引用的文献
1
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.ADCT-402（Loncastuximab Tesirine）治疗复发/难治性 B 细胞非霍奇金淋巴瘤的 I 期研究，Loncastuximab Tesirine 是一种新型的吡咯苯并二氮杂卓类抗体药物偶联物。
Clin Cancer Res. 2019 Dec 1;25(23):6986-6994. doi: 10.1158/1078-0432.CCR-19-0711. Epub 2019 Nov 4.
2
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.嵌合抗原受体 T 细胞疗法在复发/难治性侵袭性 B 细胞非霍奇金淋巴瘤临床实践中的应用：来自美国移植和细胞治疗学会的专家小组意见。
Biol Blood Marrow Transplant. 2019 Dec;25(12):2305-2321. doi: 10.1016/j.bbmt.2019.08.015. Epub 2019 Aug 22.
3
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
4
Management of relapsed/refractory DLBCL.复发/难治性弥漫性大B细胞淋巴瘤的管理
Best Pract Res Clin Haematol. 2018 Sep;31(3):209-216. doi: 10.1016/j.beha.2018.07.014. Epub 2018 Jul 23.
5
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.CD19 抗体 MOR208 治疗复发或难治性 B 细胞非霍奇金淋巴瘤的 IIa 期研究。
Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.
6
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.ADCT-402，一种含有吡咯并苯二氮䓬二聚体的抗体药物偶联物，针对表达 CD19 的恶性肿瘤。
Blood. 2018 Mar 8;131(10):1094-1105. doi: 10.1182/blood-2017-10-813493. Epub 2018 Jan 3.
7
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
8
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.弥漫性大B细胞淋巴瘤一线含利妥昔单抗的化疗免疫疗法早期失败并不能预测自体造血细胞移植无效。
Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5.
9
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
10
CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.CD19抗原在白血病和淋巴瘤的诊断及免疫治疗中的应用
Leuk Lymphoma. 1995 Aug;18(5-6):385-97. doi: 10.3109/10428199509059636.
Zotero 插件